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TMETHODS A retrospective review of a single site’s experience with AVR was done. We
looked at documentation/coding, post-operative admissions and the impact of the
transfer penalty. From 11/2007 through 7/2012, 110 patients were coded with major
complications of co-morbidities (220). We then looked at patients admitted to the
post anesthesia unit (PACU) compared to the intensive care unit (ICU). 25 patients
from 6/2013 through 12/2013 met protocol criteria and were admitted to the PACU and
62 to the ICU. We also analyzed the impact of the transfer policy of a sampling of 20
patients.
RESULTS The documentation review of the 110 patients coded with 220 revealed that
59(53%) had evidence which supported acute on chronic heart failure and may have
been eligible for a major complication or co-morbidities (219) diagnosis related group
(DRG). The post-operative admission demonstrated 25 patients admitted to the PACU
with an average length of stay (LOS) 4.42(4.46) days and the 62 patients admitted to
the ICU average LOS was 8.38(6.54) days. 38% of the PACU patients were coded with
219 and 33% with 220. The difference in weighed DRG is 2.6274units. The patients
who were discharge where the transfer penalty applied had a greater than $2000.00
loss per procedure.
CONCLUSION Advancement in healthcare comes with a price. In today’s healthcare
economy institutions continue to balance cost with being able to ofﬁce the community
the latest technology and treatment. This discussion suggests that there is cost saving
opportunities however more research is needed to truly understand the impact.
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OBJECTIVE Transcatheter Aortic Valve Replacement (TAVR) has emerged as an
alternative to high-risk surgery in patients with comorbid conditions. The role of
TAVR in patients with liver disease has not been fully examined.
METHODS We examined the procedural and intermediate to long-term follow-up
outcomes of patients at our institution with aortic valve stenosis and chronic liver
disease, identiﬁed by liver biopsy or from a combination of clinical ﬁndings. All pa-
tients were treated with Sapien or Sapien XT (Edwards Life Sciences, Irvine CA)
balloon-expandable transcatheter bioprosthesis between Nov 2007 and Feb 2014.
RESULTS A total of 17 of 706 (2.41%) patients treated with transfemoral (TF) [n¼14] or
transapical (TA) [n¼3] TAVR had liver disease (mean age 77.79.1 years, 10 men, mean
STS score 8.4, mean MELD score 11.4, Child-Turcotte-Pugh (CTP) Class A [n¼11], B
[n¼6], C [n¼0]). Median follow-up was 466 days (range ¼ 12-1403 days). In-hospital
mortality was 5.88% and 90-day mortality was 17.65%. Safety and efﬁcacy endpoints
as deﬁned by the Valve Academic Research Consortium (VARC) were signiﬁcant for
one perioperative death from a proximate cardiac cause (post-op day 14), one death
after hospital discharge of unknown cause (post-op day 12), two deaths from non-
cardiac causes (post-op days 50 and 487), and one death of unknown cause (post-op
day 1005). There were no life-threatening or major bleeding complications. One pa-
tient had a myocardial infarction, one had a transient ischemic attack, and ﬁve had
transient acute kidney injury.
CONCLUSION TF and TA TAVR are feasible methods in treating aortic stenosis in
patients with liver disease. In patients with mild to moderate liver disease there are
acceptable early and late complications, however, outcomes in patients with
advanced liver disease (MELD > 20 or CTP class C) warrants further study.
Figure 1. Kaplan-Meier Curve of Survival after TAVR
Long term survival of patients with chronic liver disease after TAVR. *Only 2
patients had follow up beyond 1000 days.CRT-804
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BACKGROUND Studies investigating the impact of procedural access on outcome of
severe aortic stenosis (AS) patients undergoing transcatheter aortic valve replace-
ment (TAVR) have shown conﬂicting results. Our aim was to characterize baseline
differences between TAVR patients undergoing via transfemoral (TF) and transapical
(TA) approaches, evaluate the risk for peri-procedural complications, and assess the
impact of access type on early and late mortality.
METHODS Severe AS patients undergoing TAVR at our institution between May 2007
and July 2014 were included. Baseline demographic, clinical and imaging parameters
were compared between TA and TF patients, peri-procedural complications rate were
assessed as well as early and late mortality rates.
RESULTS Among 548 severe AS patients undergoing TAVR, TF approach was used in
428 and TA in 120. Main differences between the 2 groups consisted from lower BMI
in the TA group along with a higher rate of peripheral vascular disease in comparison
with the TF patients. Procedural data indicates shorter ﬂuoroscopy time and smaller
contrast volume in the TA group.
Complications rate were signiﬁcantly higher in the TA group compared with TF
group, with higher AKI rates (18% vs. 5%, p<0.001), major bleeding (15% vs. 6%,
p¼0.002), pleural effusion (23% vs. 4%, p<0.001) and atrial ﬁbrillation (31% vs.
9%, p¼0.004). In addition, an increased mortality rate at 30 days was noticed among
the TA groups in comparison with TF patients (18% vs. 6%, p<0.001). However,
mortality beyond 30 days revealed was similar among both groups (16% vs. 15%,
p¼0.73).
CONCLUSION TA approach TAVR portends increased risk for serious peri-procedural
complications when compared with TF patients. TA patients have higher early mor-
tality in comparison with TF patients; however, mortality rate is similar among pa-
tients surviving the procedure.CRT-805
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the contemporary
treatment of choice for high/prohibitive surgical risk patients with severe symp-
tomatic aortic stenosis.
METHODS Outcomes of consecutive 275 (61% female) severe aortic stenosis patients,
treated with TAVI and followed up to 3 years (mean 702 days), were analyzed and
reported according to the Valve Academic Research Consortium 2 deﬁnitions. The
primary end point was death from any cause.
RESULTS This patient group (60% women) was characterized by advanced age (mean
81.76.8), high mean logistic EuroScore ¼ 19.112 and STS score ¼ 8.15. The
